Skip to main content
. 2017 Dec 17;9(2):2876–2886. doi: 10.18632/oncotarget.23355

Figure 2. Survival analysis and treatment.

Figure 2

A. Progression Free Survival (PFS) and B. Overall Survival (OS) curves according to treatment arm. Median PFS was 10.8 and 10.5 months, and median OS was 18.1 and 28.1 months, in FOLFIRI+B*12 and FOLFIRI+B*6 arm, respectively.